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ABSTRACT 
Title: Management for Spinal-Induced Hypotension in Elective Cesarean Section 
 
Background: Spinal anesthesia (SA) is the preferred method of anesthesia for cesarean 
section, but is associated with hypotension and bradycardia, which may be deleterious to both 
parturient and baby. Numerous studies reporting the incidence are as high as 80-100% if 
without adequate prophylaxis. Currently, several methods have been described to reduce the 
incidence of spinal anesthesia induced hypotension during cesarean delivery, including left 
uterine displacement, vascular filling with crystalloid or colloid, use of lower-leg 
compression and vasopressors, but no single technique has been confirmed to be completely 
effective. Recent studies suggest that ondansetron also affects hypotension and phenylephrine 
by infusion is emerging as the vasopressor of choice, titrate to baseline pressure. 
 
Purpose: The purpose of this case study is to utilize current evidence on anesthetic 
management with maternal hypotension under spinal anesthesia, including administration of 
ondansetron before spinal anesthesia, optimizing patient preload/co-load with intravenous 
fluid and vasopressor administration.  
 
Process: An initial literature search with MEDLINE and CINAHL were undertaken (year 
1990 to 2016), to find all quantitative studies that parturients of any ethnicity underwent 
spinal anesthesia for elective cesarean delivery, followed by analysis of the text words 
contained in the abstract and the index terms used to describe the article. A secondary search 
using all identified keywords, additional reports were from reference lists of retrieved articles 
and a total of 32 articles were obtained. Search engines including CINAHL, MEDLINE, 
Nursing@OVID and Clinical Key were utilized. Only studies published in English and year 
2010 onwards were considered unless that study was pertinent in this topic. Only RCT and 
meta- analysis were considered for the review. 
 
Results: Prophylaxis administration of ondansetron and preload/ co-load method were 
adopted. The patient in the case report did not encounter maternal hypotension or 
nausea/vomiting after administration of spinal anesthesia. No prophylactic phenylephrine 
infusion or other vasopressor boluses were required during the procedure. 
Implications: There is no single method that prevents spinal induced hypotension. 
Keywords: cesarean section, spinal anesthesia, ondansetron, vasopressor, phenylephrine, 
ephedrine, prophylaxis, hypotension 
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Management for Spinal-Induced Hypotension in Elective Cesarean Section 
 In the United States (U.S.), spinal anesthesia is used for the majority of elective and 
about half of emergency cesarean deliveries. Spinal anesthesia (SA) has become the gold 
standard anesthetic technique for elective cesarean section (Trabelsi et al., 2015). It is a 
simple, fast performed, powerful, and reliable technique that avoids the depressant effects of 
anesthetic drugs, and allows the mother to be awake during and immediately after delivery 
(Friedly & Simmons, 2015). In addition, spinal anesthesia is preferable than general 
anesthesia (GA) as GA is associated with a higher incidence of hemorrhage – the leading 
cause of maternal death worldwide. Also, GA requires securing the parturient airway by 
tracheal intubation, which has an increased failure rate that is eight times higher (one in 274) 
than the general population (Friedly & Simmons, 2015). Both problems lead to an increase in 
mortality.  
 Despite the popularity of SA, it is not without side effects. Maternal hypotension is a 
well-known complication with numerous studies reporting the incidence as high as 80-100% 
if without adequate prophylaxis (Hessen et al., 2016; Gao et al., 2015), and is associated with 
other adverse effects such as bradycardia, nausea and vomiting. If severe, maternal 
hypotension can result in detrimental consequences to the mother such as dyspnea, loss of 
consciousness, aspiration, and cardiac arrest (Hessen et al., 2016). These complications can 
significantly impact patient outcomes. Hence, identification of interventions for effective 
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prevention and/or proactive minimization of hypotension is imperative for improved safety to 
both parturient and fetus.   
Case Report 
 A 38-year-old, 58.6kg, 1.55m, gravida 3, para 2, 39 weeks’ gestation, ASA 2 female, 
presented for an elective cesarean section with tubal ligation. On admission, vital signs were: 
blood pressure (BP) 138/70 mm Hg, heart rate (HR) 76 /min, respirations 20/min, 
temperature of 36.5 oC with a Body Mass Index was 32.8 kg/m2. Laboratory values were 
hemoglobin 11.6 gm/dL, and platelet count of 228,000 µL. Her previous two pregnancies 
were uncomplicated and deliveries were uneventful. Her surgical history included two 
previous cesarean sections and a tonsillectomy in childhood. Medical history was 
unremarkable. Her current medication consisted solely of prenatal vitamins. She had no 
known drug allergies and no history of anesthetic complications. A preoperative examination, 
including airway evaluation was performed and her airway was classified as Mallampati II, 
thyromental distance greater than three fingerbreadth and neck with full range of motion. 
An 18-gauge peripheral intravenous catheter was in place and the patient has preloaded 
with Lactated Ringers (LR) 800ml (10ml/kg) before she was brought to the operating room. 
For placement of the spinal anesthetic, the patient was assisted to a sitting position and 
standard monitoring was initiated. Landmarks were identified and the patient was prepped 
and draped in the normal sterile fashion. An introducer needle was placed between L3 and L4 
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interspace and then a 25 gauge Whitacre spinal needle was inserted. Upon return of 
free-flowing CSF and no blood, bupivacaine 0.75% 1.4ml (10.5mg), fentanyl 20 mcg and 
morphine 0.2mg were injected and positive swirl times two observed during injection. 
Ondansetron 4 mg IV was given immediately after the spinal anesthetic was administered. 
The patient was then placed in supine with left uterine displacement and a T4 dermatome 
level was obtained.  
Oxygen was administered via nasal cannula at 3L/min and cefazolin 2 gm IV was given 
prior to incision for infection prophylaxis. The first vital sign after spinal placement was BP 
137/68 mmHg, HR 105/min and NBP were monitored every 2.5 minutes. The SBP were 
between 135 – 120 mmHg before skin incision and then 134 – 105 mmHg for the whole 
procedure. The patient had no nauseous feeling and no vasopressors (ephedrine/ 
phenylephrine) was given. The fetus was delivered 15 minutes after incision. An infusion of 
oxytocin 20 units in a 1000 ml bag of LR was commenced after delivery. A viable infant 
weighing 7 pounds 8 ounces with Apgar scores of 8 and 9 at 1 and 5 minutes respectively. 
The estimated blood loss for the case was 700 ml and 1500 ml of LR was administered 
intraoperatively.  
 The patient was transported to the post anesthesia care unit (PACU) on room air. She did 
not experience PONV nor require additional pain medication in the PACU. A postoperative 
hemoglobin was 10.4 gm/dL, which was slightly lower than the preoperative hemoglobin. By 
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postoperative day 3, the patient was doing well; ambulating, voiding, tolerating general diet. 
Her pain was well controlled with oral pain medications, and was discharged to home. 
Methodology 
 The comprehensive search strategy for the literature review was aimed to find all 
quantitative studies that include parturients of any ethnicity underwent spinal anesthesia for 
elective cesarean delivery were considered. An initial search of MEDLINE and CINAHL 
were undertaken (year 1990 to 2016) followed by analysis of the text words contained in the 
title and abstract and the index terms used to describe the article. A secondary search using all 
identified keywords, additional reports were identified from reference lists of retrieved 
articles and a total of 32 articles were obtained. Only meta-analyses and research studies that 
were randomized controlled trials were considered for the review.  
 Keywords and text words with alternate spellings: cesarean section OR cesarean 
delivery, spinal anesthesia, ondansetron OR 5-HT3 antagonist, vasopressor OR phenylephrine 
OR ephedrine, prevention OR prophylaxis, hypotension OR low blood pressure. Search 
engine including CINAHL, MEDLINE, Nursing@OVID and Clinical Key were utilized. 
Only studies published in English and year 2010 onwards were considered unless a particular 
study was pertinent to the topic of maternal hypotension following spinal anesthesia.  
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Discussion 
 Spinal anesthesia is produced by the injection of local anesthetic, often together with an 
opioid adjunct, into the subarachnoid space, with the objective of blocking conduction in 
afferent sensory fibers that transmit pain impulses to the brain. However, the conduction 
block from a local anesthetic is non-specific and preganglionic fibers to the sympathetic 
chain are also affected, resulting in sympathetic block and hypotension which can cause 
hypoperfusion of the uterus and placenta (Khaw et al., 2006). 
Risk Factors  
 Pregnancy by itself is a risk factor for hypotension under neuraxial block for several 
reasons: epidural vein engorgement and dural sac compression by the gravid uterus, together 
with greater sensitivity to local anesthetics gives a higher level of block for a given dose of 
local anesthetic (Ngan Kee, 2010). Pregnancy also tends to induce a relative increase in 
sympathetic activity making the effects of blockade more profound (Hobbs & Cockerham, 
2013). Other risk factors including preoperative hypertension, age older than 35, 
pregestational body mass index greater than 25 kg/m2, low birth gain in pregnancy, peak 
sensory block height > T4 – T6, oxytocin use, high resting sympathetic tone (resting heart 
rate > 80-90 beats per minutes or high preoperative anxiety score), high infant birth weight 
(Hobbs & Cockerham, 2013). 
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Management of hypotension during regional anesthesia in obstetric has traditionally 
been based on the results of animal experiments in pregnant ewes that were performed mainly 
under general anesthesia in the 1960s and 1970s. In particular, these studies showed that large 
doses of vasopressors caused vasoconstriction in the uteroplacental circulation, which could 
result in fetal hypoxia (Khaw et al., 2006). This led to an emphasis on non-pharmacological 
methods of management of hypotension and the establishment of ephedrine as the 
vasopressor of choice in obstetric patients. However, the results of current clinical research 
have questioned the traditional teaching and are having a major influence on the way that we 
manage hypotension during spinal anesthesia in obstetrics. 
 Early research to prevent or minimized spinal hypotension focused primarily on 
techniques to increase blood volume and venous return such as fluid loading, positioning to 
minimize aorto-caval compression, and leg wrapping. However, these techniques have 
proven largely ineffective (Gao et al., 2015). In recent years, many studies have linked 
maternal hypotension following spinal anesthesia to Bezold-Jarish reflex (BJR), a form of 
vaso-vagal syncope triggered by the sympathetic blockade and resulting decreased peripheral 
vascular resistance (Friedly & Simmos, 2015). 
Patient Positioning 
 The use of left uterine displacement or table tilt to prevent aortocaval compression is a 
routine in obstetric anesthesia that is supported by history and tradition (Hobbs & Cockerham, 
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2013). However, Khaw (2006) claimed that there is no clear evidence to support the use of 
any particular angle of tilt, the optimal degree of tilt is unknown and anesthesiologists often 
overestimate the amount they apply. Bamber and Dresner (2003) randomly looked into 33 
women during the third trimester in seven positions including full lateral, supine and various 
degrees of right and left table tilt. Apart from the FULL left lateral position in which the 
patients’ cardiac output was significantly higher, they found no benefit whatsoever between 
the untilted supine position, and the different tilted positions ranging from 2.5 to 12.5 
degrees.  
Similarly, a randomized study done by Matorras (1998) cited in Khaw (2006) that 
compared 204 women undergoing emergency cesarean section, of whom 30 received spinal 
anesthesia found no benefit from a 20-degree table tilt compared with the supine position. 
There is probably marked individual variability in the susceptibility to aortocaval 
compression and according to Khaw (2006), it is likely that only a small proportion of 
women undergoing cesarean section will have aortocaval compression that is severe enough 
to benefit from lateral table tilt. In the case study, the patient was placed in supine with left 
uterine displacement with a wedge under right buttock as this is the usual practice of the 
institution. 
Mechanisms of Hypotension During Spinal Anesthesia  
 The risk of profound hypotension is higher with spinal anesthesia than with epidural 
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anesthesia, because the onset of the sympathectomy is more rapid and dosing is not titrated.  
Initially, hypotension is caused by a decrease in systemic vascular resistance (SVR) following 
pre-ganglionic sympathetic blockade, which leads to peripheral vasodilation and venous 
pooling (Hessen et al., 2016). Thus, the decrease in blood return to the heart can easily lead to 
hypotension. 
 An additional explanation for hypotension in patients undergoing subarachnoid 
anesthesia is the Bezold-Jarisch reflex (BJR) (Terkawi et al., 2015). This reflex is mediated 
by serotonin receptors (5-HT3 sub-type) located on the vagus nerve and within the wall of the 
cardiac ventricles. They are activated by serotonin released in response to systemic 
hypotension and cause an increase in efferent vagal signaling. Serotonin induces arterial and 
venous constriction during hypovolemic states in both humans and animals through an 
interaction with α-adrenergic receptors and serotoninergic receptors (5-HT2A subtypes). As a 
result, activation of the BJR causes further inhibition of sympathetic outflow and shifts the 
cardiac autonomic balance towards parasympathetic dominance, inducing bradycardia while 
further exacerbating hypotension and vasodilation (Friedly and Simmons, 2015). Research 
found 5-HT3 (serotonin) as a potential factor that contributes to induction of the BJR by 
activating serotonin-sensitive chemoreceptors, especially in the presence of decreased blood 
volume (Sahoo et al., 2012; Owczuk et al., 2008). 
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Ondansetron  
 Mechanism of action. Ondansetron is a selective 5-HT3- receptor antagonist, blocking 
serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor 
trigger zone. 
 Dose. For prevention of postoperative nausea and vomiting, a single dose is 0.1 mg/kg 
(≤ 40 kg) and 4 mg (≥ 40kg) given approximately 30 minutes before the end of anesthesia. 
No dosage adjustment is required for patients that are elderly and/or have renal impairment. 
The maximum daily dose for hepatic impairment is 8mg (Baughman, Golembiewski, 
Gonzales, & Alvarez, 2011). 
Side effects. There are several known side effects with ondansetron. The most common, 
those > 10% reported in adult patients, include headache (9 to 27%), malaise/ fatigue (9 to 
13%), and constipation (6 to 11%). The specific treatment for ondansetron overdose has not 
been reported (Wang et al., 2014).  
 Cost. The hospital purchase cost of ondansetron 4 mg IV for an institution within North 
Dakota is US $0.29 (K. Kern, personal communication, 2017).  
Use of 5-HT3 Antagonist in Bezold- Jarisch Reflex Induced Hypotension 
 Friedly and Simmons (2015) stated that ondansetron is a highly effective and specific 5- 
HT3 receptor antagonist. Therefore, it is strongly believed that ondansetron preloading before 
spinal anesthesia may prevent hypotension by blocking 5-HT- triggered BJR, suppressing 
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further expansion of peripheral vessels and increasing blood return to the heart. 
 Routinely, ondansetron is used for treatment of postoperative nausea, vomiting and 
intraoperative chills. It was also found effective in preventing hypotension after spinal 
anesthesia (Wang et al., 2014). Few studies have been conducted to evaluate the effects of 
5-HT3 antagonist on BJR induced hypotension. Sahoo and colleagues (2012) conducted a 
double-blind randomized, placebo-controlled study on 56 obstetric patients who were ASA 
physical status I, between 20 and 40 years of age undergoing a lower segment cesarean 
section with spinal anesthesia. Patients were randomly allocated into two groups receive 
either intravenous ondansetron 4mg or normal saline 5 minutes before spinal anesthesia. 
Heart rate (HR), systolic (SBP), diastolic (DBP) and mean arterial pressure (MAP) and 
oxygen saturation (SpO2) were recorded at the time of spinal drug administration and at 2 
minutes’ intervals up to 20 minutes, followed by 5 minutes’ intervals until the end of surgery. 
SBP <90 mmHg or DBP < 60 mmHg was treated with IV phenylephrine 50 µg; HR < 50 
beats/min was treated with IV atropine 0.3mg. Nausea and vomiting were treated with IV 
promethazine 12.5mg. Their result indicated that ondansetron prevented the 
serotonin-induced BJR, suppressed venodilatation, augmented venous return to the heart and 
result in lesser reduction in SBP and MAP (Sahoo et al., 2012). 
  Similarly, the clinical presentation of this case study is consistent with Sahoo’s 
study. In this case, the time of ondansetron administration had been discussed with the CRNA. 
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Eventually, ondansetron 4 mg was given right after the parturient was brought into the 
operating room and then placed in the sitting position for spinal anesthesia. Both SBP and 
DBP from spinal injection towards delivery of fetus were within 20% of patient’s baseline. 
The parturient had no complaints of nausea and no vasopressors was given throughout the 
procedure. Thus, it is possible that the reduction in SBP and MAP were secondary to the 
administration of IV ondansetron before spinal anesthesia. This would be consistent with one 
of the results noted in Sahoo’s 2012 study. Given that few studies have been done in this area, 
more research needs to be done in the future to determine if this is a valid relationship that is 
generalizable. 
Optimal Time and Dosage for Ondansetron Injection 
Ondansetron has been studied previously for use in spinal anesthesia (Owczuk et al., 
2008; Sahoo et al., 2012; Wang et al., 2014; Trabelsi et al., 2015; Khouly, 2016). These 
studies all concluded that ondansetron 4mg given intravenously 5 minutes before a 
subarachnoid block reduced maternal hypotension and the occurrence of nausea and vomiting, 
as well as vasopressor required in parturient women undergoing elective cesarean deliveries. 
In addition, the results indicated that ondansetron prevent the serotonin-induced BJR, 
suppressed venodilatation, augmented venous return to the heart and resulted in lesser 
reductions in SBP and MAP.      
Likewise, meta-analyses done by Gao et al. (2015) and Hessen et al., (2016) have 
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similar conclusions. Gao and colleagues (2015) analysis ten randomized controlled trial with 
863 patients with the effects of prophylactic ondansetron on spinal anesthesia- induced 
hypotension. In eight of ten studies, ondansetron was administrated 5 minutes before spinal 
anesthesia. They found the relative risk (RR) of hypotension after ondansetron in the obstetric 
subgroup was 0.16 (95% CI 0.05 to 0.51, P= 0.002). The RR of bradycardia after 
prophylactic ondansetron was 0.27 (95% CI 0.16 to 0.47, P < 0.0001), indicating that 
prophylactic ondansetron significantly reduced the incidence of bradycardia caused by spinal 
anesthesia. In addition, they found the mean difference (MD) of ephedrine consumption after 
prophylactic ondansetron administration was -2.35mg (95% CI -4.14 to – 0.55 mg, P < 0.05), 
suggesting that prophylactic ondansetron significantly reduced the required dose of 
ephedrine.     
 Similarly, Heesen et al. (2016) reviewed and analyzed seventeen (8 obstetric, 9 
non-obstetric) RCT trials on 2604 patients. The aim of the review was to determine whether 
5-HT3 receptor antagonists administered before the initiation of spinal anesthesia mitigate 
hypotension. They concluded that 5-HT3 antagonists are effective in reducing the incidence 
of hypotension and bradycardia; the effects are moderate and are only significant in the 
patients undergoing cesarean delivery. Though the effects in the non-obstetric population are 
not significant. 
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 Although conventional practice and previous studies have shown that ondansetron 4mg 
preloading can significantly reduce maternal hypotension and nausea, the dose-dependent 
effect of ondansetron has not been investigated (Wang et al., 2014). Therefore, Wang and 
colleagues (2014) designed a double-blinded randomized study to compare the efficacy of 
different doses of ondansetron preloading combined with rapid crystalloid coloading on 
reducing maternal hypotension during cesarean delivery, they also assessed the effects of 
different doses on maternal nausea, umbilical venous pH, partial pressure of carbon dioxide 
(Pco2), bicarbonate (Hco3) and base excess in extracellular fluid and neonatal outcome after 
delivery.  
A total of 150 participants were randomly assigned to one of five groups according to 
computer-generated codes, 30 women in each group. Five minutes prior to spinal anesthesia, 
the participants in the five groups were intravenously injected with 5ml of physiological 
saline (S) or 2mg (02), 4mg (04), 6mg (06) or 8mg (08) of ondansetron. If hypotension 
occurred (defined as systolic blood pressure less than 80% of baseline), an IV bolus of 
pnenylephrine100 µg was given in the study period (30 minutes). The results revealed that 
the incidence of maternal hypotension was significantly reduced in groups 04 and 06 (p< 0.05) 
and no bradycardia or vomiting was observed in groups 04, 06 and 08.   
 Moreover, the consumption of phenylephrine in group 04 was significantly less than that 
in group S (Wang et al., 2014). Regarding neonatal outcome, the gas analysis results from 
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umbilical arterial blood showed that there was no significant difference in pH, Pco2, PO2, 
Hco3or base excess (P> 0.05). The pH of the umbilical venous blood was significantly higher 
in group 04 compared with group S.   
  Concerning the maternal hemodynamic parameters, the maximum decline of SBP, 
DBP and MAP was significantly lower in group 04, while minimal changes of mean of SBP, 
DBP, MAP and HR were observed in group 04 and 06. Wang’s (2014) study demonstrated 
that IV injection of 4 or 6 mg of ondansetron paired with preloading of a rapid crystalloid 
infusion could significantly reduce the incidence of maternal hypotension and nausea, 
decrease the Pco2 in umbilical venous blood, and stabilize the maternal hemodynamics. 
However, lower (2mg) and higher (8mg) doses of ondansetron preloading failed to reduce the 
incidence of maternal hypotension and nausea. Additionally, 6mg and 8mg of ondansetron 
might cause light lactate acidosis in the fetus according to the reduced BE value. Therefore, 
considering its effects on hypotension, nausea, phenylephrine consumption and neonatal 
outcomes, 4 mg of ondansetron preloading was the optimal dose to prevent maternal 
hypotension, nausea and other adverse effects during cesarean delivery per Wang’s (2014) 
result. 
Intravenous Fluid Therapy – Preload versus Co-load 
  The American Society of Anesthesiologists Practice Guidelines for Obstetric 
Anesthesia (2007) state that fluid preloading may reduce the frequency of maternal 
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hypotension. Traditionally, crystalloid intravenous fluids were administered before the 
induction of spinal anesthesia for cesarean delivery (preload). The rationale for preload is to 
maintain or augment cardiac preload and cardiac output (CO) and thus prevent or attenuate 
hypotension. If the requirement for vasopressor drugs can be reduced, the risk of consequent 
uteroplacental vasoconstriction may be decreased. Common practice is to infuse 
approximately 1-2 liters or 10 – 20 ml/kg of lactated Ringer’s (LR) solutions while the 
patient is being prepared for regional anesthesia. Early studies describing fluid preloading 
had impressive result and became established as an accepted standard of care (Khaw et al., 
2006). However, its use has now been largely abandoned due to its relative lack of efficacy in 
reducing spinal-induced hypotension, even when used in large volumes (Tawfik et al., 2014).  
More current evidence has shown that preloading may be unsuccessful in reducing the 
incidence of hypotension for a number of reasons. Khaw et al. (2006) claimed that the poor 
efficacy probably reflects rapid redistribution and short clinical half-life (20 to 30 minutes) of 
crystalloid – only 28% of crystalloid remains in the intravascular compartment when given 
over 30 minutes. Banerjee et al. (2010) explained that early fluid loading is not effectively 
increase the intravascular volume at the time of maximum vasodilation. A rapid infusion of 
LR solution increases the intravascular volume by about 10%, but it decreases rapidly when 
the infusion is discontinued. On the other hand, preloading may induce atrial stretching, 
releasing atrial natriuretic peptide. Since natriuretic peptide type C is a potent vasodilator 
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produced in the endothelium of great vessels, rapid fluid administration (whether before or 
during induction of anesthesia) may actually exacerbate peripheral vasodilation and facilitate 
fluid excretion.     
 In the meta-analysis review by Banerjee and colleagues (2010), the authors aimed to 
determine whether the timing of the fluid infusion, before (preload) or during (co-load) 
induction of spinal anesthesia for cesarean delivery influences the incidence of maternal 
hypotension or neonatal outcome. They were unable to conclude the time of fluid loading, 
either before or during induction of spinal anesthesia, affected the incidence of hypotension 
or other side effects in patients undergoing elective cesarean delivery. None of their reviewed 
studies, that involved total 518 patients, showed a statistically significant difference in the 
incidence of hypotension between groups. They concluded that the timing of fluid loading 
does NOT have an impact on the incidence of hypotension and that is true for both colloid 
and crystalloid loading.  
 In contrast, a study by Williamson et al. (2009) hypothesized that administering half of 
the fluid bolus (10ml/kg) before and half immediately following injection of the SAB would 
provide benefit in reduction of spinal-induced hypotension in parturient. In the RCT study, 87 
ASA I or II subjects were investigated. 43 preload (control) and 44 preload/coload 
(experimental). Subjects assigned to the control group received a 20ml/kg fluid bolus of LR 
during approximately 20 minutes in the preoperative holding area. This bolus was timed to be 
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completed just before transport to the operative suite. Once the fluid bolus was given, the 
infusion rate was decreased to a maintenance rate of 100ml/hr. The experimental group 
received a 10ml/kg LR preload beginning approximately 10 minutes before transport to the 
operative suite, and then received a maintenance infusion of 100ml/hr during placement of 
the SAB. Immediately following injection of the SAB, all subjects in the experimental group 
were administered an IV bolus of 10ml/kg of LR during approximately 10 minutes and then 
received a maintenance infusion of 100ml/hr until the conclusion of the cesarean delivery. 
Hypotension in the study was defined as an SBP of less than 100mmHg or a decrease in mean 
arterial pressure (MAP) of 20% from the baseline.  
The results indicated that, compared with control group, the total volume of LR infused 
was significantly less (P = 0.02) in the experimental group. Analysis of vasopressor use 
revealed that 31 (72%) of 43 subjects in the control group required ephedrine for blood 
pressure support compared with 24 (55%) of 44 subjects in the experimental group (P = 0.09). 
The amount of ephedrine and phenylephrine used was higher in the control group than in the 
experimental group, but this finding did not achieve statistical significance (P > 0.05). The 
authors recommended replacing standardized prophylactic crystalloid fluid administration 
(20ml/kg preload) with preload/co-load method as described.  
 In the case report, the parturient was given intravenous fluid in this manner 
(preload/co-load). She was infused with LR 800ml 10 minutes before brought into the 
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operating room and 800ml (10ml/kg) co-load right after the spinal injection, then 100ml per 
hours afterward towards the end of surgery. 
Colloid versus Crystalloid 
 In contrast to crystalloids, colloid solutions have a longer intravascular half-life and are 
more effective than crystalloids in reducing the incidence as well as the severity of 
hypotension (Morgan et al., 2001). Recent studies have described the use of albumin, gelatins 
and hetastarch solutions, some in combination with crystalloids. Using 15ml/ kg of 5% 
albumin, hypotension was prevented and better condition of the baby was reported and when 
500ml of 6% hetastarch was used to supplement crystalloid preload, the incidence of 
hypotension was halved from 85% to 45% (Khaw et al., 2006).  
 In a randomized double-blind study by Tawfik et al. (2014), 210 patients were randomly 
allocated to received either 6% hydroxyethyl starch 500ml before spinal anesthesia (colloid 
preload) or Ringer’s acetate solution 1000ml administered rapidly starting with intrathecal 
injection (crystalloid co-load). They concluded the use of 1000ml crystalloid co-load has 
similar effect to 500ml colloid preload and neither technique can totally prevent hypotension 
and should be combined with vasopressor use. Moreover, colloid is expensive and have 
potential risks of allergic reactions, disease transmission, and fluid overload, which limits 
general acceptance in routine clinical practice.   
 The anesthesia professional should be vigilant in fluid boluses and total fluid infused 
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due to the physiologic changes associated with pregnancy, which places parturient patients 
are at an increased risk for the development of pulmonary edema. The risk is increased in the 
setting of large fluid boluses that are often required during spinal anesthesia (Williamson, 
2009).  
Vasopressors – Ephedrine versus Phenylephrine   
 In choosing an appropriate vasopressor in obstetrics, several factors need to be 
considered. These include efficacy, maternal effects other than increasing blood pressure, 
ease of use, direct and indirect fetal effects, cost, and availability (Ngan Kee & Khaw, 2006). 
 Vasopressors drugs increase BP by increasing SVR (by vasoconstriction) and/or by 
increasing CO (by increasing contractility and HR). Postsynaptic α1-receptors in peripheral 
vessels mediate vasoconstriction and stimulation of postsynaptic β1-receptors in the heart 
increases HR and cardiac contractility.  
 Ephedrine. Ephedrine is a mixed α and β receptor agonist. Its mechanism is both direct 
(binds and stimulates receptors) and indirect (causes release of norepinephrine from 
presynaptic vesicles). Ephedrine causes an increase in cardiac contractility, HR, CO and 
systolic and diastolic BP (Lee et al., 2002). It has a slow onset of action and limited efficacy 
in prevention and treatment of hypotension. According to Kluger (2000), large doses may be 
required which increases the chances of unwanted effects. Acute tolerance to ephedrine 
develops and phenylephrine may need to be added when ephedrine is ineffective or when a 
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large dose has been given. When large doses of ephedrine are used to restore BP, sustained 
increases above baseline may occur (Lee et al., 2002). In particular, an important concern 
about ephedrine in obstetric has been the association between its use and a dose-related 
depression of fetal pH and base excess.  
 Although a decrease in uteroplacental blood flow is a possible explanation, the data from 
animal studies suggest that this is unlikely. An alternative explanation, according to Cooper 
(2012), is a direct stimulating effect on fetal metabolism. Ephedrine has metabolic 
stimulatory effects that has led to its use for weight loss and athletic performance 
enhancement in adults. Metabolic stimulation is particularly noted in brown adipocytes and is 
thought to be medicated by stimulation of β-adrenoreceptors. Ephedrine crosses the placenta 
and increase fetal catecholamine concentrations.  
 Ngan Kee and Khaw (2006) stated that an increase in umbilical arterial norepinephrine 
concentrations was shown to correlate with decreasing pH. Maternally administered 
ephedrine increases fetal heart rate and fetal tachycardia can often be observed on the 
cardiotocograph when large doses of ephedrine are given before delivery in clinical practice. 
 Phenylephrine. Phenylephrine is chemically related to adrenaline but 
pharmacodynamically similar to norepinephrine. It is a potent, rapidly-acting vasopressor 
with a short duration of action that selectively stimulates α-1 adrenoreceptors with very little 
activity on the β-1 adrenoreceptors of the heart. It increases systolic and diastolic BP in a 
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dose-dependent manner based purely on its α-1 adrenoreceptor action (Khaw et al., 2006). 
 Despite different methods described above in preventing and treating hypotension in 
obstetric anesthesia including IV fluid preload/ co-load and prophylactic preload with 5-HT3 
antagonist, vasopressor is often required. Two commonly used and investigated vasopressors 
by anesthesia providers are ephedrine and phenylephrine. In fact, there is growing evidence 
that the choice of vasopressor for treatment of maternal hypotension from spinal anesthesia is 
controversial (Khaw et al., 2006). The main issues surround efficacy and hemodynamic 
effects as well as the potential for adverse effects on uteroplacental blood flow and fetal 
acid-base status as discuss above.  
 Historically, ephedrine was recommended based on observations in pregnant sheep that 
showed it was more effective for increasing arterial pressure with better preservation of 
uteroplacental blood flow compared with other vasopressors. This was explained by 
ephedrine’s predominant β-effect that caused an increase in arterial pressure by increasing 
cardiac output rather than by vasoconstriction. As such, the use of pure α-agonist such as 
phenylephrine has generally been avoided because of concerns about their potential adverse 
effect on uterine blood flow (Lee, 2002). 
 However, extrapolation from animal studies to humans may not be always appropriate 
because there are species differences and differences in dose, titration and duration of the 
administration, and use of IV prehydration to consider (Lee, 2002). In fact, in the systematic 
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review by Lee (2002), there was no clear evidence that phenylephrine was associated with 
decreased uterine blood flow because there were few RCTs examining this issue.  
In addition, her finding is actually indirect evidence that uterine blood flow may be 
better with phenylephrine compared with ephedrine. It can be explained that relatively large 
total doses of ephedrine were required to maintain maternal arterial pressure and the fact that 
ephedrine exhibits marked tachyphylaxis because its sympathomimetic effects are largely 
indirect, arising from the release of noradrenaline form postganglionic sympathetic nerve 
endings that may become depleted after repeated dosing of action and long duration of action. 
These factors mean that ephedrine may be more difficult to titrate, especially compared with 
direct-acting vasopressors, which may contribute to suboptimal control of arterial pressure 
(Lee, 2002).  
Subsequently, Ngan Kee and Lee (2008) investigating different factors that may predict 
uterine arterial pH and base excess, and the authors concluded that in order to minimize the 
risk of fetal acidosis, ephedrine should NOT be used before delivery and that α-agonist 
should be the choice for minimizing spinal hypotension. Heesen and colleagues (2015) 
concurred that there is no advantage to routinely using ephedrine in combination with 
phenylephrine because it increases maternal nausea compared with phenylephrine alone, 
phenylephrine has become firmly established as the vasopressor of choice, for both 
prophylaxis and treatment of spinal hypotension in obstetrics. 
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Vasopressor Infusion 
    Currently, research continues to focus on optimizing the administration of 
phenylephrine. Areas studied have included: how phenylephrine could best be administered; 
whether it should be used proactively (prophylactically) or reactively (only when spinal 
hypotension has occurred); whether continuous infusions are superior to bolus administration 
and the appropriate dose or doses required to avoid unwanted side effects such as reactive 
hypertension and bradycardia (Hessen, 2015).  
A meta-analysis looking at the use of phenylephrine for cesarean section under spinal 
anesthesia by Hessen (2014) concluded that a continuous infusion (proactive treatment) 
started immediately after initiation of spinal anesthesia can effectively reduce hypotension 
and nausea without inducing fetal acidosis compared with bolus doses given only in response 
to a fall in SBP (reactive treatment). It needs to be given immediately following induction of 
spinal anesthesia because of the rapid decrease in systemic vascular resistance. Prophylactic 
phenylephrine bolus administration should be followed by an infusion or repeated bolus 
because of its short duration of action (Cooper, 2012).  
Although some anesthesia professionals regard prophylactic administration of 
phenylephrine as too aggressive, the review by Hessen (2014) revealed that the risk of 
reactive hypertension did not differ between prophylactic and reactive regimens and the risk 
of bradycardia was also similar between groups.  
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     In order to develop the reliably and safely infusion regimen that will control the 
maternal blood pressure, with minimal maternal side-effects while avoiding maternal 
hypertension, Ngan Kee and colleagues (2005) conducted their studies in phenylephrine 
infusion regimen. An infusion of phenylephrine 100 µg/min was started immediately after 
completion of the intrathecal injection and was continued for the first 2 minutes unless SBP 
exceeded 120% of baseline, in which case it was stopped. After this, the infusion was 
continued if SBP was less than or equal to baseline, and stopped once it went above baseline. 
Patient were randomly assigned to two groups depending on the crystalloid infusion received, 
either a rapid infusion (co-load) group or a minimal maintenance group and they found that 
total phenylephrine consumption was lower in the group receiving co-hydration. 
 Other authors have studied different infusion regimens of phenylephrine ranging from 
25 to 100 µg/min. Studies by Stewart et al. (2010) and Heesen (2015) both suggested that 
compared with higher doses, 25 – 50 µg/min offers the most favorable risk/ benefits profile, 
that is, the lowest rate of both hypotension and hypertension.   
 In this case study, no phenylephrine infusion has been infused whatsoever as it was not 
the usual practice of the institution. Phenylephrine and ephedrine syringe bolus were ready to 
go but eventually SBP and MAP were maintained and no complained of nausea or emesis, 
thus no vasopressor was given in this case.  
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The Future Practice – How About Norepinephrine? 
Recently, norepinephrine has emerged as a potential alternative agent for the treatment 
of spinal-induced hypotension in obstetric anesthesia (O’Sullivan & Cockerham, 2016). The 
reason is the mixed α and β agonist activity of norepinephrine may make it preferable drug 
for maintaining blood pressure with less bradycardia and no difference in fetal outcome. 
In the previous discussion, it was noted that, as compared with ephedrine, phenylephrine 
is associated with less neonatal acidosis while maintaining uteroplacental blood flow. 
However, it has also been shown that phenylephrine can have clinically significant side 
effects such as baroreceptor medicated bradycardia with a consequent decrease in cardiac 
output (Vallejo et al., 2016). Norepinephrine has weak β- adrenergic receptor agonist activity 
and therefore may be a more suitable option for maintaining maternal blood pressure with 
less negative effects on HR and CO compared with phenylephrine. According to Ngan Kee 
(2015), although treatment of hypotension during spinal anesthesia is listed by the 
manufacturer as an indication for the use of norepinephrine, there is limited information 
available for its use for this purpose in the literature and few reports of its used in obstetric 
patients.  
In the recent double-blinded, randomized controlled study by Ngan Kee (2015), 104 
healthy patients having cesarean delivery under spinal anesthesia were randomized to have 
SBP maintained with a computer-controlled infusion of norepinephrine 5 µg/ml or 
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phenylephrine 100 µg/ml. The primary outcome compared was cardiac output, blood pressure, 
heart rate and neonatal outcome were also compared. The authors found that an infusion of 
norepinephrine maintained blood pressure as effectively as phenylephrine, but with less 
bradycardia and less decrease in cardiac output. Also, no significant differences in neonatal 
outcomes were found. In this study, utilizing minimally invasive cardiac output monitors 
have demonstrated marked reduction in systemic vascular resistance and a modest increase in 
cardiac output, heart rate and stroke volume after induction of spinal anesthesia. This 
physiological observation is consistent with the findings that α-agonist vasopressors are the 
most reliable method for preventing and treating spinal hypotension during cesarean delivery. 
Another randomized controlled clinical trial by Vallejo et al. (2016) hypothesized that 
norepinephrine would be superior to phenylephrine, and requiring fewer rescue bolus 
interventions to maintain blood pressure. Eighty-five parturients having spinal anesthesia for 
elective cesarean delivery were randomized to Group P (phenylephrine 0.1 µg/kg/min) or 
Group N (norepinephrine 0.05 µg/kg/min) fixed-rate infusion. Rescue bolus interventions of 
phenylephrine 100 µg for hypotension, or ephedrine 5mg for bradycardia with hypotension, 
were given as required to maintain SBP. The results confirmed the authors’ clinical 
impression that a fixed rate infusion of norepinephrine is effective for maintaining maternal 
blood pressure in elective cesarean delivery under spinal anesthesia. When a norepinephrine 
infusion was used, the number of required rescue boluses of ephedrine was decrease and 
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fewer patients had emesis compared with a phenylephrine infusion.  
     Despite the encouraging results from Ngan Kee (2015), Vallejo et al. (2016) and 
more work is coming out, it is quite certain that it would be unlikely another paradigm shift in 
vasopressor choice for cesarean delivery. Carvalho (2015) claimed that although there is 
strong evidence that phenylephrine is a superior agent to ephedrine (e.g. faster onset of action, 
better fetal acid-base profile, less placental drug transfer, and more effective at increasing 
systemic vascular resistance), it took many years for clinicians to change practice and for 
phenylephrine to be considered the drug of choice in this setting.  
 In contrast, norepinephrine is generally use in the intensive care and cardiac anesthesia 
setting. Given this lack of familiarity, the shift toward using norepinephrine in the obstetric 
domain will be challenging. Anesthesia professionals will likely require much convincing 
with additional research in this area before they are ready for another vasopressor paradigm 
shift in the management of spinal hypotension during cesarean delivery. 
Evidence Based Recommendations 
Clinical Recommendations – Preload/ Co-load plus 5- HT3 Antagonist 
     In summary, there is no single method that prevents spinal induced hypotension and 
the management continues to be controversial. In this paper, current management on healthy 
parturient had been reviewed and the changing trend has been discussed. Prophylactic 5-HT3 
antagonist had a significant effect on the incidence of hypotension in healthy parturient, most 
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of the studies result support to administer intravenous ondansetron 4 mg five minutes before 
spinal anesthesia. Crystalloid pre-hydration seems to be of little use and the current focus is 
on the timing of administration of fluid – preload 10ml/kg (20 minutes before procedure) 
together with coload 10ml/kg (given in 10 minutes after SAB) instead of preload 20ml/hr - 
this is based on the half-life of crystalloid stay intravascularly. Though, it is unnecessary to 
delay surgery in order to deliver a preload of fluid. Regardless of the fluid loading strategy, 
the incidence of maternal hypotension is high.  
Clinical Recommendations – Vasopressor 
Prophylactic or therapeutic vasopressors likely to be required in a significant proportion 
of patients. Base on the review of plentiful meta-analysis on cesarean delivery vasopressor 
management, the current best-practice recommendation is for phenylephrine infusion starting 
at 50 mcg/min right after spinal injection and then titrate to response, with bolus if needed. 
Most experts and academic units have moved away from the use of ephedrine because of its 
poor efficacy, greater placental transfer and association with fetal acidosis. Thus, it may be 
prudent to avoid ephedrine before the baby is delivered. But it can be useful when given after 
delivery because of its longer duration of action.  
Future Research  
 More RCT’s work should be conducted to determine the safety of norepinephrine in 
obstetric patients and investigate whether its use may be associated with greater 
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uteroplacental blood flow compared with phenylephrine, particularly in conditions where 
uteroplacental perfusion is restricted such as preeclampsia. Lastly, it is imperative to 
determine the optimal infusion rate and dosing strategy of norepinephrine for maintaining 
maternal hemodynamics under spinal anesthesia for cesarean delivery. 
Conclusion 
Based on the clinical presentation of this case study and review of the latest evidence, a 
combination of pharmacological and non-pharmacological methods is beneficial in 
minimizing maternal hypotension following spinal anesthesia in cesarean delivery. Several 
methods have been described including left uterine displacement, vascular filling with 
crystalloid preload/ co-load, use of lower-leg compression, vasopressors (bolus versus 
infusion), as well as intravenous ondansetron 4mg given five minutes before spinal anesthesia 
may reduce hypotension, phenylephrine requirements and nausea. However, no single 
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Appendix A: North Dakota Association of Nurse Anesthetists Meeting Presentation 
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